CCM
CGEM icon

CAAS Capital Management’s Cullinan Oncology CGEM Stock Holding History

CAAS Capital Management’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-60,000
Closed -$2.5M – 1070
2021
Q1 		$2.5M Buy
+60,000
New +$2.44M 0.03% 540

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

CAAS Capital Management's CGEM Position: Q2 2021 in Review

CAAS Capital Management sold out of Cullinan Oncology (CGEM) in Q2 2021, closing a stake of 60,000 shares — an estimated $2.5M sold.

CAAS Capital Management first reported a position in CGEM in Q1 2021 and held it in 1 quarter. The position peaked at $2.5M in Q1 2021. 71 funds tracked by Wall St. Rank hold CGEM as of Q2 2021.

  • CAAS Capital Management reported no remaining Cullinan Oncology position as of Q2 2021 after selling out during the quarter.
  • CAAS Capital Management sold 60,000 Cullinan Oncology shares in Q2 2021, an estimated $2.5M.
  • CAAS Capital Management first reported a position in Cullinan Oncology in Q1 2021 and held it in 1 quarter.
  • CAAS Capital Management's Cullinan Oncology position peaked at $2.5M in Q1 2021.
  • 71 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2021.

Based on CAAS Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.